Institutional members access full text with Ovid®

Share this article on:

Isoniazid preventive therapy for postrenal transplant tuberculosis: a systematic review

Wang, Xiandinga; Zhuang, Jingb; Xie, Liboa; Li, Mingyuanc,d; Lu, Yipinga

Reviews in Medical Microbiology: January 2011 - Volume 22 - Issue 1 - p 5–11
doi: 10.1097/MRM.0b013e3283410434

We have systematically evaluated published randomized controlled trials (RCTs) on the efficacy and safety of isoniazid preventive therapy (IPT) in renal transplant recipients. Electronic databases Medline, Embase, and Cochrane Library (up to April 2010) were searched to identify relevant publications. Two reviewers independently applied the study selection criteria, examined study quality and extracted data. Data were expressed as risk ratios with 95% confidence intervals (CIs), and all statistical analyses were performed using Review Manager 5.0. Three RCTs met our selection criteria, including 657 patients (300 versus 357). Differences between IPT and control for post-transplant tuberculosis (TB) (risk ratios = 0.38; 95% CI 0.12–1.16; P = 0.09), extrapulmonary TB (risk ratios = 0.28; 95% CI 0.02–4.85; P = 0.38), TB-related deaths (risk ratios = 6.32; 95% CI 0.27–150.32; P = 0.25), and hepatitis (risk ratios = 1.05; 95% CI 0.72–1.55; P = 0.78) were not statistically significant. None of the three RCTs reported serious adverse effects related to IPT. On current evidence, IPT cannot be recommended as routine practice for the prevention of postrenal transplant TB, even in countries where TB is endemic.

aDepartment of Urology, West China Hospital, People's Republic of China

bDepartment of Obstetrics and Gynecology, West China Second University Hospital, People's Republic of China

cDepartment of Medical Microbiology, West China School of Preclinical and Forensic Medicine, People's Republic of China

dState Key Laboratory of Oral Diseases, Sichuan University, Chengdu, Sichuan, People's Republic of China.

Received 3 August, 2010

Revised 28 September, 2010

Accepted 28 September, 2010

Correspondence to Professor Yiping Lu, Department of Urology, West China Hospital, Sichuan University, Number 37, Guoxue Alley, Chengdu, Sichuan 610041, People's Republic of China. Tel: +86 18 980601426; fax: +86 28 85422451; e-mail:

© 2011 Lippincott Williams & Wilkins, Inc.